Literature DB >> 33489491

Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of Literature.

Hiya Boro1, Suraj Kubihal1, Saurabh Arora2, Vijay Kubihal3, Nikhil Tandon4.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) or Wermer's syndrome is a genetic disease characterized by involvement of multiple endocrine glands, primarily involving parathyroid, pancreas, and pituitary. Other additional features include foregut carcinoids; non-functioning adrenal tumors; and skin lesions such as lipomas, collagenomas, and angiofibromas. Here, we describe our experience in managing a patient who presented to us with spontaneous episodes of hypoglycemia and was diagnosed with insulinoma. Detailed clinical and biochemical evaluation unraveled the diagnosis of MEN1 in the patient and her family members who constituted a large kindred. This case highlights the importance for evaluation of MEN1 in a patient or his/her family members in the setting of clinical and biochemical suspicion. In addition, we have also discussed the utility of the latest diagnostic and therapeutic modalities for management of MEN1.
Copyright © 2020, Boro et al.

Entities:  

Keywords:  insulinoma; pancreatic net; parathyroid adenoma; pituitary adenoma

Year:  2020        PMID: 33489491      PMCID: PMC7805507          DOI: 10.7759/cureus.12073

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  11 in total

Review 1.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

Authors:  Rajesh V Thakker; Paul J Newey; Gerard V Walls; John Bilezikian; Henning Dralle; Peter R Ebeling; Shlomo Melmed; Akihiro Sakurai; Francesco Tonelli; Maria Luisa Brandi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-20       Impact factor: 5.958

2.  Minimally invasive parathyroidectomy without intraoperative parathyroid hormone monitoring: when and why?

Authors:  M Barczynski
Journal:  J Postgrad Med       Date:  2009 Oct-Dec       Impact factor: 1.476

3.  Parathyroid hyperplasia may be missed by double-phase Tc-99m sestamibi scintigraphy alone.

Authors:  E M Chen; F S Mishkin
Journal:  Clin Nucl Med       Date:  1997-04       Impact factor: 7.794

4.  Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study.

Authors:  P H Kann; E Balakina; D Ivan; D K Bartsch; S Meyer; K-J Klose; Th Behr; P Langer
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

5.  Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1).

Authors:  Jeremy J O Turner; Paul T Christie; Simon H S Pearce; Peter D Turnpenny; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

Review 6.  Rapid intraoperative immunoassay of parathyroid hormone and other hormones: a new paradigm for point-of-care testing.

Authors:  Lori J Sokoll; Frank H Wians; Alan T Remaley
Journal:  Clin Chem       Date:  2004-04-29       Impact factor: 8.327

7.  Cause of death in multiple endocrine neoplasia type 1.

Authors:  S Wilkinson; B T Teh; K R Davey; J P McArdle; M Young; J J Shepherd
Journal:  Arch Surg       Date:  1993-06

Review 8.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

Review 9.  Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia.

Authors:  Diva D De León; Charles A Stanley
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-09       Impact factor: 4.690

Review 10.  Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old.

Authors:  Alberto Falchetti
Journal:  F1000Res       Date:  2017-01-24
View more
  1 in total

1.  Multiple endocrine neoplasia type 1 with ectopic parathyroid adenoma.

Authors:  Qiaorui Liu; Liming Wu; Xulei Zheng; Cong Ma; Risu Na; Ling Qiu; Zhiwen Liu; Liyan Liao
Journal:  Arch Med Sci       Date:  2022-04-14       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.